References

Unresolved reference

External reference

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

10.1210/jc.86.8.3853 · 2001 · External reference

UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years

10.1002/(sici)1096-9136(199804)15:4<297::aid-dia572>3.3.co;2-n · 1998 · External reference

Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity

10.2337/diabetes.48.10.2001 · 1999 · External reference

Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase

10.1016/j.diabres.2006.12.021 · 2007 · External reference

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

10.2337/diacare.27.6.1335 · 2004 · External reference

One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes

10.2337/diabetes.53.5.1187 · 2004 · External reference

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

10.2337/diacare.27.8.1915 · 2004 · External reference

The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with type 2 diabetes

2002 · External reference

Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes

2004 · External reference

Liraglutide significantly improves glycaemic control, and lowers body weight without risk of either major or minor hypoglycaemic episodes in subjects with type 2 diabetes

2006 · External reference

Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas

10.2337/diacare.19.8.857 · 1996 · External reference

Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?)

10.1210/en.140.2.778 · 1999 · External reference

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice

10.1152/ajpendo.00030.2002 · 2002 · External reference

Unresolved reference

External reference

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

10.1111/j.1463-1326.2009.01194.x · 2010 · External reference

Tolerability, pharmacokinetics, and pharmacodynamics of liraglutide, long acting human GLP-1 analogue

2007 · External reference

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

2010 · External reference

Clinical studies of liraglutide, a novel, once-daily human glucagon-like peptide-1 analog for improved management of type 2 diabetes mellitus

10.1592/phco.29.pt2.43s · 2009 · External reference

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)

10.1111/j.1464-5491.2009.02666.x · 2009 · External reference

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)

10.2337/dc08-2124 · 2009 · External reference

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes

10.2337/dc08-1355 · 2009 · External reference

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

10.1016/s0140-6736(08)61246-5 · 2009 · External reference

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with type 2 diabetes

10.1111/j.1464-5491.2005.01567.x · 2005 · External reference

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

10.2337/dc06-2593 · 2007 · External reference

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

10.1185/03007991003672551 · 2010 · External reference

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats

10.1210/en.2002-220405 · 2002 · External reference

Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis

10.1074/jbc.m209423200 · 2003 · External reference

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

10.1210/en.2002-220897 · 2003 · External reference

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro

10.1016/j.bbrc.2005.03.013 · 2005 · External reference